Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.55 |
| ▸ | PI4KA | P42356 | 7/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 7/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 7/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 7/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | AHCY | P23526 | 5/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1272854 | 0.79 | ADORA2A (0.51) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL14125909 | 0.78 | ADORA2A (0.51) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL283730 | 0.78 | FGFR1 (0.51) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL9275563 | 0.78 | ADORA2A (0.49) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28296105 | 0.78 | ADORA2A (0.47) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28113155 | 0.77 | GSK3B (0.51) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL16485904 | 0.77 | GSK3B (0.48) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28406876 | 0.77 | ADORA2A (0.50) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL27818519 | 0.76 | ADORA2A (0.50) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL9458754 | 0.75 | PI4KA (0.56) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150231177-A1 | Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2015-08-20 | — | — | US | claimed |
| US-20120207793-A1 | Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications | VIRGINIA COMMONWEALTH UNIVERSITY | 2012-08-16 | — | — | US | claimed |
| EP-2252333-A2 | GAS BASED WOUND AND TISSUE THERAPEUTICS | Oxygen Biotherapeutics, Inc. (US) | 2010-11-24 | — | — | EP | claimed |
| WO-2009102487-A2 | GAS BASED WOUND AND TISSUE THERAPEUTICS | OXYGEN BIOTHERAPEUTICS, INC. (US) | 2009-08-20 | — | — | WO | claimed |
| US-20090169630-A1 | Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications | VIRGINIA COMMONWEALTH UNIVERSITY | 2009-07-02 | — | — | US | claimed |
| EP-2024287-A1 | METHODS AND COMPOSITIONS FOR CONTROLLED AND SUSTAINED PRODUCTION AND DELIVERY OF PEROXIDES | Virginia Commonwealth University (US) | 2009-02-18 | — | — | EP | claimed |
| WO-2007134304-A1 | METHODS AND COMPOSITIONS FOR CONTROLLED AND SUSTAINED PRODUCTION AND DELIVERY OF PEROXIDES | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2007-11-22 | — | — | WO | claimed |
| US-20150231177-A1 | Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2015-08-20 | — | — | US | disclosed |
| US-20130289471-A1 | GAS BASED WOUND AND TISSUE THERAPEUTICS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2013-10-31 | — | — | US | disclosed |
| US-20120207793-A1 | Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications | VIRGINIA COMMONWEALTH UNIVERSITY | 2012-08-16 | — | — | US | disclosed |
| US-20120184898-A1 | GAS BASED WOUND AND TISSUE THERAPEUTICS | TENAX THERAPEUTICS, INC | 2012-07-19 | — | — | US | disclosed |
| US-8101117-B2 | Controlled gas pore formers in extruded ware | CORNING, INCORPORATED (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2252333-A2 | GAS BASED WOUND AND TISSUE THERAPEUTICS | Oxygen Biotherapeutics, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20090298667-A1 | Controlled Gas Pore Formers in Extruded Ware | CORNING INCORPORATED | 2009-12-03 | — | — | US | disclosed |
| WO-2009102487-A2 | GAS BASED WOUND AND TISSUE THERAPEUTICS | OXYGEN BIOTHERAPEUTICS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090202617-A1 | Gas based wound and tissue therapeutics | TENAX THERAPEUTICS, INC | 2009-08-13 | — | — | US | disclosed |
| US-20090169630-A1 | Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications | VIRGINIA COMMONWEALTH UNIVERSITY | 2009-07-02 | — | — | US | disclosed |
| EP-2024287-A1 | METHODS AND COMPOSITIONS FOR CONTROLLED AND SUSTAINED PRODUCTION AND DELIVERY OF PEROXIDES | Virginia Commonwealth University (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2009006586-A2 | SELF-CONTAINED OXYGEN GENERATING AND BREATHING SYSTEMS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2007134304-A1 | METHODS AND COMPOSITIONS FOR CONTROLLED AND SUSTAINED PRODUCTION AND DELIVERY OF PEROXIDES | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202617-A1 | Gas based wound and tissue therapeutics | PGF, FGF2, FGF1 | ADORA2A 2174/4885ADORA1 2826/4885PI4KA 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.